<DOC>
	<DOCNO>NCT00632463</DOCNO>
	<brief_summary>RSV infection develop serious , life threatening condition among immunocompromised patient . The objective study ( ADMA 001 ) evaluate safety efficacy RI-001 prevention lower respiratory tract infection immunocompromised patient identify infected RSV upper respiratory tract .</brief_summary>
	<brief_title>RI-001 Immunosuppressed Respiratory Syncytial Virus ( RSV ) Infected Patients Risk Lower Tract RSV Illness</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<criteria>1 . An IEC/IRB approve write informed consent sign dated patient parent ( ) legally acceptable representative . The consent form specific assent form , require , sign dated minor . 2 . Documented Bone Marrow Transplant ( BMT ) /Hematopoietic Stem Cell Transplant ( HSCT ) , Pulmonary/Cardiac Transplant , Pulmonary Transplant Liver Transplant within 2 year prior randomization study drug . 3 . Male/Female patient age : ( Pediatric ) ≥2 year &lt; 16 year time inform consent . 4 . Male/Female patient age : ( Adult ) ≥ 16 year ≤ 65 year time inform consent . 5 . Patient must URTI defined Respiratory Assessment Score ( RAS ) =1 . 6 . Patients must actively take least one immunosuppressive agent . 7 . Patients must positive RSV RTPCR time randomization procedure . 8 . Female patient must nonchildbearing potential negative pregnancy test prior study start deem risk become pregnant adherence reliable contraceptive method duration study . Females nonchildbearing potential defined woman hysterectomy , bilateral oophorectomy , tubal ligation postmenopausal least two year , consider sterile due recent chemotherapy . 9 . Female patient breastfeed . 10 . Patient/legally acceptable representative consider reliable capable adhere protocol ( e.g . able understand complete diary questionnaire ) , visit schedule treatment regimen accord judgment Investigator . 1 . Documented RSV low respiratory tract infection ( respiratory assessment score great 1 ) determine site investigator research staff . 2 . Requirement mechanical ventilation , extracorporeal membrane oxygenation , continuous positive airway pressure mechanical respiratory cardiac support 3 . Unstable respiratory status severe survival expect longer 6 month . 4 . End organ dysfunction result anticipated survival le 6 month . 5 . Known HIV positive . 6 . Administration RSV specific product , include palivizumab ( Synagis® ) 3 month prior randomization procedure . 7 . Previous , current , planned administration investigational RSV vaccine . 8 . Known hypersensitivity immunoglobulin . 9 . Known Immunoglobulin ( IgA ) deficiency 10 . Known renal impairment require form dialysis ( HD , PD , CRRT ) . 11 . Known hemodynamically significant congenital heart disease . 12 . Previous poor compliance visit schedule . 13 . Severe medical , neurological psychiatric disorder laboratory value may impact safety patient . 14 . Concurrent participation investigational drug product study ; exception must approve ADMA Biologics Medical Director .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Transplant</keyword>
	<keyword>Immunosuppression</keyword>
</DOC>